CytomX Therapeutics to Present at Upcoming September Investor Conferences
September 04 2024 - 7:00AM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of
masked, conditionally activated biologics, today announced that
management will participate in the following investor conferences
in September.
H.C. Wainwright 26th
Annual Global Investment ConferenceDate:
Wednesday, September 11, 2024 Formal Presentation: 12:30 p.m. ET
Location: New York, NY
2024 Cantor Global Healthcare ConferenceDate:
Thursday, September 19, 2024Fireside Chat: 9:45 a.m. ET Location:
New York, NY
Live webcasts of the H.C. Wainwright presentation and Cantor
fireside chat will be available on the Events and Presentations
page of CytomX’s website at www.cytomx.com. In addition, management
will be available for one-on-one meetings with investors who are
registered to attend the conferences.
About CytomX TherapeuticsCytomX is a
clinical-stage, oncology-focused biopharmaceutical company focused
on developing novel conditionally activated, masked biologics
designed to be localized to the tumor microenvironment. By
pioneering a novel pipeline of localized biologics, powered by its
PROBODY® therapeutic platform, CytomX’s vision is to create
safer, more effective therapies for the treatment of cancer.
CytomX’s robust and differentiated pipeline comprises therapeutic
candidates across multiple treatment modalities including
antibody-drug conjugates (“ADCs”), T-cell engagers, and immune
modulators such as cytokines. CytomX’s clinical-stage pipeline
includes CX-904, CX-2051 and CX-801. CX-904 is a masked,
conditionally activated T-cell-engaging bispecific antibody
targeting the epidermal growth factor receptor (EGFR) on tumor
cells and the CD3 receptor on T cells. CX-904 is partnered with
Amgen in a global co-development alliance. CX-2051 is a masked,
conditionally activated ADC directed toward epithelial cell
adhesion molecule (EpCAM) and armed with a topoisomerase-1
inhibitor payload. CX-2051 has potential applicability across
multiple EpCAM-expressing epithelial cancers and was discovered in
collaboration with ImmunoGen, now part of AbbVie. CX-801 is a
masked interferon alpha-2b PROBODY® cytokine with broad
potential applicability in traditionally immuno-oncology sensitive
as well as insensitive (cold) tumors. CytomX has established
strategic collaborations with multiple leaders in oncology,
including Amgen, Astellas, Bristol Myers Squibb, Regeneron and
Moderna. For more information about CytomX and how it is working to
make conditionally activated treatments the new standard-of-care in
the fight against cancer,
visit www.cytomx.com and follow us
on LinkedIn and X (formerly
Twitter).
Company Contact:Chris OgdenSVP,
Chief Financial Officercogden@cytomx.com
Investor Contact:Precision AQ
(formerly Stern Investor Relations)Stephanie
Ascherstephanie.ascher@precisionaq.com
Media Contact:Redhouse
CommunicationsTeri Dahlmanteri@redhousecomms.com
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Oct 2024 to Nov 2024
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Nov 2023 to Nov 2024